Clinical Trials Directory

Trials / Completed

CompletedNCT01642069

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
30 Years
Healthy volunteers
Not accepted

Summary

This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL). Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer

Detailed description

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved mRNA Study Population Description: Samples from AAML0531 Sampling Method: Non-Probability Sample OBJECTIVES: I. To determine whether NUP98/JARID1A expression is a recurrent translocation in NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL). II. To screen the Children Oncology Group (COG) samples for genetic aberrations in pediatric AMKL. OUTLINE: Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression profiling by reverse transcriptase polymerase chain reaction (RT-PCR) and karyotyping or fluorescence in situ hybridization (FISH). Results are then compared with each patient's outcome data.

Conditions

Interventions

TypeNameDescription
OTHERlaboratory biomarker analysisCorrelative studies

Timeline

Start date
2012-07-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2012-07-17
Last updated
2016-05-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01642069. Inclusion in this directory is not an endorsement.